Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 in Myelofibrosis and Indolent Systemic Mastocytosis
NCT04655118Phase 2Recruiting
- Sponsor
- Telios Pharma
- Start
- Oct 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of TL-895 in myelofibrosis (MF), indolent systemic mastocytosis (ISM), sponsored by Telios Pharma. Started Oct 2020; status: recruiting.
02
Drugs
TL-895
03
Conditions
myelofibrosis (MF)indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on NCT04655118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655118.